Efficacy and Tolerability of Perampanel in Patients with Sodium Channel Mutations
Abstract number :
2.242
Submission category :
4. Clinical Epilepsy / 4C. Clinical Treatments
Year :
2024
Submission ID :
802
Source :
www.aesnet.org
Presentation date :
12/8/2024 12:00:00 AM
Published date :
Authors :
Presenting Author: khalid hundallah, MD – PSMMC
Rationale: We aimed to explore the potential of perampanel, as a precision therapy on patients with epilepsy caused by sodium channel mutations.
Methods: All patients with epilepsy caused by sodium channel mutation were collected from 4 tertiary centers in Saudi Arabia. All patients with refractory epilepsy older than 4 years were started on perampanel as and add on. Outcome measures were responce rate (50% seizure reduction) and percentage of seizure reduction after 3 months of treatment.
Results: We identified 26 patients with epilepsy caused by sodium channel mutation older than 4 years. A total of 18 patients had refractory epilepsy and were included in our study. All of the patients were on one to three anti-seizure medications prior to initiation of perampanel. Perampanel was added in all of them due to persistent seizures. Overall response rates were 55% and 66% at 6 months and 12 months, respectively. None of stopped perampanel due to its side effects.
Conclusions: This preliminary pilot study outlines a research project demonstrating the safety and efficacy of Perampanel in patients with sodium channel mutaion, especially in SCN1A and SCN8A, suggesting a targeted effect related to glutamate transmission.
Funding: none
Clinical Epilepsy